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Abstract
Topoisomerase 1 (TOP1) inhibitors, including camptothecin and topotecan, covalently trap
TOP1 on DNA, creating cleavage complexes (cc’s) that must be resolved before gene tran-
scription and DNA replication can proceed. We previously found that topotecan reduces the
expression of long (>100 kb) genes and unsilences the paternal allele of Ube3a in neurons.
Here, we sought to evaluate overlap between TOP1cc-dependent and -independent gene
regulation in neurons. To do this, we utilized Top1 conditional knockout mice, Top1 knock-
down, the CRISPR-Cas9 system to delete Top1, TOP1 catalytic inhibitors that do not gener-
ate TOP1cc’s, and a TOP1 mutation (T718A) that stabilizes TOP1cc’s. We found that
topotecan treatment significantly alters the expression of many more genes, including long
neuronal genes, immediate early genes, and paternal Ube3a, when compared to Top1 dele-
tion. Our data show that topotecan has a stronger effect on neuronal transcription than
Top1 deletion, and identifies TOP1cc-dependent and -independent contributions to gene
expression.
Introduction
Topoisomerases are enzymes that resolve DNA supercoils by creating transient single (Type I
topoisomerases) or double (Type II topoisomerases) strand breaks [1,2]. These enzymes facili-
tate DNA replication, chromosomal segregation, DNA repair, and gene transcription [3]. In
postmitotic cells, topoisomerases predominantly regulate gene transcription and DNA repair
[4]. Topoisomerase I (TOP1) relieves DNA supercoiling ahead of RNA polymerase to facilitate
transcription elongation [5–7]. Although the roles of topoisomerases in dividing cells have
been studied extensively, much less is known about their functions in neurons.
Long noncoding RNAs (lncRNA) can act as transcriptional activators or repressors in post-
mitotic neurons and other cell types [8,9]. Ube3a antisense (Ube3a-ATS) is an extremely long
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lncRNA (> 1 Mb) and is expressed exclusively from the paternal allele in most neurons during
development and throughout adulthood. Paternal expression of Ube3a-ATS silences the pater-
nal copy of Ube3a via a transcriptional collision mechanism [10–12].
We previously found that TOP1 and TOP2 inhibitors unsilence the paternal allele of Ube3a
in postmitotic neurons by reducing expression of Ube3a-ATS [13]. Mutations that reduce or
increase UBE3A function are linked to Angelman syndrome (AS) and autism, respectively
[14–21]. In addition to downregulating Ube3a-ATS, TOP1 and TOP2 inhibitors also downre-
gulate the expression of other long (generally>100 kb) genes in neurons, many of which are
associated with neurotransmission and synaptic function [22]. Consistent with reduced expres-
sion of long synaptic genes, inhibition of TOP1 with topotecan disrupts excitatory and inhibi-
tory synaptic transmission in cortical neuron cultures, an effect that is reversible following
inhibitor washout [23]. TOP1 inhibitors also reduce expression of long genes in non-neuronal
cell types [24,25].
Topotecan binds at the interface between TOP1 and DNA, creating a TOP1-DNA enzyme
intermediate known as a TOP1 cleavage complex (TOP1cc) [26]. Given this unique mecha-
nism of inhibition, we sought to determine the extent to which TOP1 and TOP1cc formation
contribute to neuronal gene expression and Ube3a regulation. To answer these questions, we
generated a Top1 conditional knockout mouse to genetically delete Top1 from cultured neu-
rons. We also utilized the CRISPR-Cas9 system to delete Top1, used short hairpin (sh)RNAs to
knock-down Top1, compared TOP1 catalytic inhibitors that do not generate TOP1cc’s to topo-
tecan, and utilized a TOP1 (T718A) mutation that stabilizes TOP1cc’s. Surprisingly, we found
that topotecan affected the expression of many more genes when compared to deletion of Top1
—the molecular target of topotecan. Taken together, our findings reveal TOP1cc-dependent
and -independent control of gene expression and Ube3a regulation in neurons. Our findings
also have implications for cancer therapies that target TOP1 via these distinct mechanisms.
Materials and Methods
Knockout first ES cells targeting the Top1 gene were acquired from the KOMP Repository
Knockout Mouse Project (Project ID: CSD36970, Top1tm1a(KOMP)Wtsi). ES cells were microin-
jected into albino C57BL/6 blastocysts by the UNC Animal Models Core Facility. Two chimeric
lines were bred for germline transmission. Successful germline transmitted mice were then
crossed to a FLP1 recombinase deleter mouse B6.Cg-Tg(ACTFLPe)9205Dym/J (Jackson Labo-
ratory) to excise the lacZ/neomycin cassette (removal confirmed by PCR), then backcrossed
further to C57Bl/6 mice to remove the Flp transgene. To distinguish genotypes for Top1 cKO
mice, the following primers flanking the LoxP site and within the Top1 gene were used: geno 2,
5’-GAGTTTCAGGACAGCCAGGA-3’ and geno 3, 5’-GGACCGGGAAAAGTCTAAGC-3’.
Neuronal Cultures
Embryonic day E13.5–15.5 mouse cortical neuron cultures were prepared by cervical disloca-
tion of adult C57BL6/J wild-type females as described [13]. Animals were kept on a 12-hour
light-dark cycle and given ad libitum access to food and water. All experimental animal proce-
dures were carried out according to the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use Committee at the University of
North Carolina at Chapel Hill. For immunostaining, dissociated neurons were plated in
24-well dishes containing poly-D-lysine (0.1 mg/ml) coated 12 mm coverslips at a density of
2.5 x 105 cells/well. For biochemistry, dissociated neurons were seeded on poly-D-lysine coated
12-well dishes at a density of 5 x 105 cells/well.
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Western Blotting
Lentiviruses harboring pLenti-CaMKIIα-tdTomato and pLenti-CamKIIα-tdTomato-
P2A-CRE based vectors were prepared by the UNC Lentiviral Core. Lentiviral Top1 shRNA
was generated as previously described [22]. Briefly, cortical neurons were transduced at DIV 3
with lentivirus at a multiplicity of infection of at least two to maximize the number of trans-
duced cells (around 85–90% transduction efficiency). Media containing lentivirus was removed
24 hours later and replaced with conditioned media. The CaMKIIα promoter limited tdTo-
mato expression to neurons and was detectable without antibody amplification 3–4 days post
transduction. Neurons were then treated at DIV 15 with vehicle (0.003% DMSO, Neurobasal
medium) or 300 nM topotecan (Molcan Corporation; in 0.003% DMSO, Neurobasal medium)
and harvested 3 days later.
For western blot experiments, cells were harvested and lysed in RIPA buffer (50 mM Tris-
HCl, 150 mMNaCl, 0.5% sodium deoxycholate, 1% Triton X-100, and 0.1% SDS, pH 7.4) with
1 mM DTT, 1 μg/mL aprotinin, 2 μg/mL leupeptin, and 0.1 mM PMSF. Total protein (25–
40 μg) was run on a 4–15% gradient SDS-PAGE gel (Bio-RAD). Proteins were then transferred
to nitrocellulose membrane, blocked overnight in Odyssey Blocking Buffer (LI-COR), and
immunoblotted overnight using the following antibodies: rabbit anti-UBE3A (1:1,000; Bethyl
Laboratories, A300-352A), mouse anti-UBE3A (1:1,000; BD Biosciences), mouse anti-NLGN1
(1:500; Synaptic Systems, 129 111), mouse anti-NRXN1 (1:500; BD Biosciences, 611882),
mouse anti-CNTNAP2 (1:1,000; NeuroMab, 75–075), mouse anti-β-actin (1:5,000; Millipore,
MAB1501R), rabbit anti-TOP1 (1:10,000; GeneTex, GTX63013), or mouse anti-TOP1 (1:250;
Santa Cruz, sc-271285). The GeneTex rabbit monoclonal antibody was raised against the N-
terminus of human TOP1. The Santa Cruz mouse monoclonal antibody was raised against the
C-terminus (amino acids 685–765) of human TOP1. Both antibodies are predicted to react
with mouse TOP1. Membranes were washed three times with water at room temperature and
the appropriate IRDye secondary antibodies (Li-COR) were added at a dilution of 1:15,000–
1:20,000 for 1 hour at room temperature. Blots were then washed two times in Tris-buffered
saline containing 0.1% Tween-20 and two times with water. Membranes were dried in the
dark and imaged using the ODYSSEY CLx Infrared Imaging System (LI-COR). Equivalent
amounts of protein per sample were loaded and loading controls were used to ensure equiva-
lent loading between samples. Experiments were performed on a minimum of three indepen-
dent culture sets.
Immunocytochemistry
Neurons were fixed for 20 min in cold phosphate buffered saline (PBS) containing 4% parafor-
maldehyde and 4% sucrose. Cells were permeabilized with 0.1% Triton X-100 in PBS for 15
min at room temperature and blocked in 10% normal goat serum (NGS) for 1 h at 37°C [27].
Neurons were then incubated with 1:1,000 mouse anti-UBE3A (Sigma, clone #330) and 1:1,000
rabbit anti-TOP1 (Genetex) in 3% NGS overnight at 4°C. Cells were washed three times with
3% NGS in PBS and incubated with a 1:1,000 dilution of Alexa dye-conjugated secondary anti-
bodies (Invitrogen) and 1:10,000 dilution of DAPI (ThermoFisher Scientific) in 3% NGS in
PBS in the dark for 1 hour at room temperature. Cells were then washed three times with PBS
and mounted on slides using FluoroGel mounting media (Electron Microscopy Sciences). To
detect TOP1 DNA covalent complexes, we utilized an antibody that specifically recognizes
TOP1-DNA covalent complexes [27]. Briefly, neurons were fixed as stated above, permeabi-
lized in 0.25% Triton X-100 in PBS for 15 min at room temperature, washed 3 times in 0.1%
Triton X-100, and then blocked in 10% NGS in PBS for 1 h at 37°C. Neurons were incubated
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with 1:1,500 dilution of mouse anti-TOP1-DNA covalent complex antibody (Millipore, clone
1.1A) in 3% NGS in PBS overnight at 4°C.
Images were acquired using a Zeiss LSM 710 upright microscope with a 20X/0.8 NA objec-
tive. Images were acquired with identical settings (gain, contrast, pinhole) for UBE3A, TOP1,
and TOP1 DNA covalent complexes. Treatment and transfected conditions were interleaved
during each imaging session. The intensity of UBE3A, TOP1, and TOP1 DNA covalent com-
plexes was quantified from maximum intensity projections in FIJI following thresholding at
least 2 standard deviations above background. For the CRISPR-Cas9 Ube3a unsilencing experi-
ments, regions of interest (ROIs) were identified by outlining the soma of tdTomato positive
neurons manually. ROIs were then transposed on both the UBE3A and TOP1 channel to mea-
sure the integrated density. Note that for the Top1 CrispR-Cas9 experiments, we excluded cells
where TOP1 was not deleted, and average TOP1 integrated density was at or above the average
TOP1 intensity in untransfected neurons. For experiments using AS::Top1fl/fl neuron cultures,
ROIs were selected automatically in FIJI. Briefly, DAPI images were thresholded and nuclei
were separated using the Watershed Tool. ROIs were then outlined using the Analyze Particles
tool with a setting size of 8 μm to infinity. The integrated density of each ROI was then trans-
posed to a thresholded (two standard deviations above background) UBE3A channel where the
integrated density was measured. ROIs were then transposed onto the GFP channel to identify
transfected and untransfected neurons.
Cloning
To generate the pLenti-CamKIIα-tdTomato and pLenti-CamKIIα-tdTomato-P2A-CRE con-
structs, tdTomato and tdTomato-P2A-CRE fragments were PCR cloned into the pLenti-Cam-
KIIα-ChR2-mCherry vector (http://www.everyvector.com/sequences/show/20437). Briefly,
ChR2-mCherry was excised and replaced with tdTomato or td-Tomato-P2A-CRE using AgeI
and BsrGI sites for tdTomato and BamHI and EcoRI sites for tdTomato-P2A-CRE. Human
GFP-TOP1 was PCR cloned into the the pLenti-CamKIIα-ChR2-mCherry vector (modified
from Karl Deisseroth’s laboratory) using AgeI and EcoRI restriction sites. The PCR template
for human TOP1 was a kind gift from Stefan Weger from the Intitut fur Virologie in Berlin,
Germany. The GFP-TOP1 cleavable complex mimetic (T718A) was created using site directed
mutagenesis using the following primer sets: 5’-AAACAGATTGCCCTGGGAGCCTCCAAACTC
AATTATC-3’ and 5’-GATAATTGAGTTTGGAGGCTCCCAGGGCAATCTGTTT-3’. CRISPR-
Cas9 targeting of Top1 was accomplished by annealing Top1 sgRNAs into the lentiCRISPR v1
vector backbone (Addgene) using the suggested cloning strategy (http://www.genome-
engineering.org/crispr/?page_id=23). A total of four Top1 sgRNA targets were designed using
the E-CRISP design tool (http://www.e-crisp.org/E-CRISP/). The following primer sets were
used to clone into the lentiCRISPR v1 backbone: Clone #1: 5’-CACCGCCGGGGCTTTTCCGA
GGCCG-3’ and 5’-AAACCGGCCTCGGAAAAGCCCCGGC-3’ Clone #2: 5’-CACCGATCGG
AAATCCGCTTCGATC-3’ and 5’-AAACGATCGAAGCGGATTTCCGATC-3’ Clone #3: 5’-
CACCGTCGGAAATCCGCTTCGATCT-3’ and 5’-AAACAGATCGAAGCGGATTTCCGAC-3’
Clone #4: 5’-CACCGAGATCGAGAACACCGGCATA-3’ and 5’-AAACTATGCCGGTGTTCT
CGATCTC-3’. Each individual clone was tested for Top1 loss by immunostaining for TOP1
protein in neurons. Clone #1 and #4 were deemed the most efficient; clone #4 was used for sub-
sequent experiments.
RNA-seq
Top1fl/fl neurons were infected with either tdTomato or tdTomato-P2A-CRE lentivirus and
treated as stated above. RNA was isolated with the RNeasy plus mini kit (Cat. #74134, Qiagen).
TOP1 Regulation of Gene Expression in Neurons
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RNA yield and quality was determined with a Nanodrop 1000 Spectrophotometer (Thermo
Scientific). Samples were further assessed for quality using either an Agilent Bioanalyzer 2100
or TapeStation 2200 to obtain a RNA integrity number (RIN). RIN values exceeding 7 were
used for sequencing. RNA samples were used to generate and barcode cDNA libraries using
the TruSeq RNA Library Preparation Kit at the UNC High Throughput Sequencing Facility.
Pools of 24 multiplexed samples were sequenced per lane in a HiSeq 2500 sequencer using 50
bp paired-end reads.
RNA-Seq Data Processing
RNA-seq reads were filtered using TagDust and aligned to the reference mouse genome (mm9)
with TopHat using default parameters. Reads aligning to rRNA genes were removed. Tran-
script abundance was estimated by computing RPKM using RefSeq gene models aggregated by
gene symbol. For differential expression analyses, raw counts over RefSeq exons were used and
compared across samples using EdgeR. RNA-seq data were deposited in the GEO database
(accession no. GSE79951).
Synthesis of TOP1 Catalytic Inhibitors
TOP1 catalytic inhibitors were synthesized and characterized as described [28–30].
Results
TOP1-Dependent Control of Neuronal Genes
The TOP1 inhibitor topotecan suppresses expression of long genes and unsilences the paternal
copy ofUbe3a in neurons [13,22]. To determine if these transcriptional effects could be recapit-
ulated by deletion of Top1, we generated a Top1 conditional knockout mouse (cKO), as homo-
zygous deletion of Top1 is embryonic lethal with failure occurring between the 4 and 16-cell
stages [31]. The Top1 cKO allele contains two LoxP sites flanking exon 3 (Fig 1A) such that
Cre-mediated excision is predicted to facilitate nonsense-mediated decay of Top1mRNA and
thus disrupt TOP1 protein levels. To confirm that Top1 can be deleted in these mice, we cre-
ated tdTomato (control) and CRE-dependent lentiviral constructs driven by the neuron-spe-
cific CamKIIα promoter (Fig 1B). Transfection of CRE, but not tdTomato, reduced TOP1
protein levels in Top1 cKO neurons (Fig 1B). Infection of Top1fl/fl cultured neurons with tdTo-
mato or CRE lentivirus resulted in a transduction efficiency ranging from 85–90% (data not
shown). TOP1 levels were maximally decreased 7 days post infection with CRE compared to
tdTomato control neurons (Fig 1C). Additionally, no lower molecular weight TOP1-reactive
bands were detected, indicating that truncated products of TOP1 are not generated in neuronal
cultures from Top1 cKO mice (S1A Fig). The residual levels of TOP1 most likely originate
from uninfected neurons and/or non-neuronal cells in the cultures.
To determine how Top1 deletion affects neuronal gene expression relative to topotecan, we
infected Top1fl/fl cortical neuron cultures with tdTomato control (WT) or CRE (Top1 cKO)
and measured changes in transcript levels via RNA-seq in cells treated with vehicle (Veh) or
topotecan (Topot) (Fig 2A). As expected, topotecan-treated WT cells (WT-Topot) exhibited
global reductions in the expression of long genes compared to vehicle-treated WT cells
(WT-Veh). Vehicle-treated Top1 cKO (Top1 cKO-Veh) cells also exhibited global reductions
in the expression of long genes compared to WT-Veh cells (Fig 2B), although the effect size
was attenuated when compared to topotecan-treated cells (Fig 2B). Topotecan treatment did
not further alter the expression of long genes in Top1 cKO cells (Top1 cKO-Topot; Fig 2B),
TOP1 Regulation of Gene Expression in Neurons
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Fig 1. Generation and validation of Top1 cKOmouse. (A) Schematic of the Top1 cKO allele. LoxP sites
flank exon 3. (B) Schematic of tdTomato (top) and tdTomato-P2A-CRE lentiviral plasmids (bottom). Top1fl/fl
neurons were transfected with tdTomato or tdTomato-P2A-CRE plasmids. Neurons were fixed and
immunostained with an anti-TOP1 antibody. Scale bar, 10 μm. (C) Cortical neurons were infected with
tdTomato or tdTomato-P2A-CRE lentivirus at DIV 3 and then were harvested at DIV 7, DIV 10, and DIV 13.
Representative immunoblots and quantification of TOP1 protein expression normalized to ACTIN (bottom).
Mean ± s.e.m., unpaired student’s t-test; * p < 0.05, n = 3 cultures.
doi:10.1371/journal.pone.0156439.g001
TOP1 Regulation of Gene Expression in Neurons
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Fig 2. Top1 deletion is necessary and sufficient for the expression of some long genes. (A) Schematic of the experimental setup
used to assess changes in transcript levels following Top1 deletion. (B) LOESS smoothing curve showing RNA-seq average log2 change in
transcript levels in topotecan-treated WT (WT-Topot, red), vehicle-treated Top1 cKO (Top1 cKO-Veh, green), and topotecan-treated Top1
cKO (Top1 cKO-Topot, blue) cortical neuron cultures relative to vehicle-treated WT (WT-Veh) cells plotted in bins of 200 genes by length.
(C) Venn diagram showing the number of significantly downregulated genes in topotecan-treatedWT (WT-Topot, red), vehicle-treated
TOP1 Regulation of Gene Expression in Neurons
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suggesting the transcriptional effects of topotecan depend on Top1 and are thus molecularly
on-target.
Relative to WT-Veh, we found multiple downregulated (Fig 2C) and upregulated (Fig 2D)
genes (FDR of< 0.01) in WT-Topot, Top1 cKO-Veh, and Top1 cKO-Topot cortical neuron
cultures. A total of 580 genes were significantly decreased in WT-Topot cells, whereas 113
genes were significantly decreased in Top1 cKO-Veh cells. Eighty of these 113 genes were
downregulated in both WT-Topot and Top1 cKO-Veh cells (S1 Table). Based on Gene Ontol-
ogy, downregulated genes in WT-Topot and Top1 cKO-Veh cells were functionally annotated
to common biological processes such as synaptic transmission and cell adhesion (S2 Table).
There was no statistically identifiable functional annotation for Top1 cKO-Topot cells in the
downregulated gene set (S2 Table). We also looked at the expression of individual genes that
were reduced in WT-Topot cells but not in Top1 cKO-Veh cells. Strikingly, a large proportion
of immediate early genes (IEGs) were decreased in WT-Topot but not in Top1 cKO-Veh cells
(S2 Fig). Moreover, relative to Top1 cKO-Veh, we did not detect a decrease in IEG expression
in Top1 cKO-Topot cells, suggesting the change in IEG expression is Top1-dependent. These
findings indicate that topotecan reduces expression of IEGs in a TOP1-dependent manner,
and that deletion of TOP1 alone does not reduce expression of IEGs. Collectively, these data
indicate that the transcriptional effects of topotecan are significantly greater than the effects of
TOP1 deletion, consistent with the fact that topotecan generates TOP1cc’s and does not simply
inhibit TOP1.
We found that 224 genes were upregulated in WT-Topot cells, whereas only 33 genes were
upregulated in Top1 cKO-Veh cells. Additionally, Top1 cKO-Topot cells had a significant
increase in 4 genes, of which 1 overlapped with WT-Topot cells (Fig 2D and S1 Table). Based
on Gene Ontology, upregulated genes in WT-Topot cells were functionally annotated to axon
guidance and cell motion processes where Top1 cKO-Veh upregulated genes were functionally
annotated to eye lens development (S3 Table).
As expected, Top1 transcript levels were reduced in Top1 cKO cells (Fig 2E). Moreover, we
observed elevated expression of Ube3a in WT-Topot but not in Top1 cKO-Veh cells (Fig 2F).
Several long synaptic adhesion genes were also downregulated in WT-Topot and Top1 cKO--
Veh cells (Fig 2G–2J), consistent with our previous findings [22]. Taken together, these data
indicate that topotecan-treatment or TOP1 deletion reduces expression of a subset of long
genes, which include extremely long synaptic adhesion genes.
Top1 Deletion Reduces Synaptic Adhesion Protein Levels
Previously, we found that topotecan downregulates synaptic proteins and dampens synaptic
transmission [23]. Here we found that conditional deletion of Top1 in cortical neuron cultures
reduced the expression of synaptic adhesion proteins to a similar extent as in topotecan-treated
WT cells (Fig 3A and 3B). Addition of topotecan to CRE-infected cells did not further decrease
protein expression, indicating that Top1 deletion occluded additional effects of topotecan on
these synaptic adhesion proteins (Fig 3A and 3B). Using an independent genetic approach, we
employed a Top1-specific lentiviral shRNA to reduce TOP1 (S3A and S3B Fig), which also
reduced the expression of two long synaptic adhesion proteins, NEUREXIN-1 and NEUROLI-
GIN-1 (S3A and S3B Fig).
Top1 cKO (Top1 cKO-Veh, green), and topotecan-treated Top1 cKO (Top1 cKO-Topot, blue) cortical neuron cultures relative to vehicle-
treatedWT (WT-Veh) cells. The FDR was set at a value of < 0.01. (D) Venn diagram showing the number of significantly upregulated
genes. (E—J) Representative transcript level changes from RNA-seq analysis. Normalized RPKM values (relative to WT-Veh) in WT-Veh,
WT-Topot, Top1 cKO-Veh, and Top1 cKO-Topot. Mean ± s.e.m., FDR < 0.1, n = 3 cultures.
doi:10.1371/journal.pone.0156439.g002
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Topotecan, but Not Top1 Deletion, Unsilences Ube3a
We next sought to determine if genetic reduction or deletion of Top1 could unsilence Ube3a in
neurons. First, we cultured cortical neurons lacking the maternal copy of Ube3am-/p+ (AS) and
transduced them with lentiviral Top1 shRNA (S3C and S3D Fig). This manipulation reduced
TOP1 protein levels but was not sufficient to unsilence Ube3a, as demonstrated by the lack of
detectable paternal UBE3A protein (S3C and S3D Fig). TOP1 protein levels were reduced
~50% in these knockdown experiments, raising the possibility that residual levels of TOP1
might maintain Ube3a-ATS transcription and hence maintain repression of paternal Ube3a.
To examine this possibility, we crossed Top1 cKO mice with AS mice, prepared cortical neuron
cultures, and transduced cells with either tdTomato control (WT) or CRE lentivirus to delete
Top1 (Top1 cKO) (Fig 4A). Neurons were then treated with vehicle or topotecan to test for the
ability to unsilence Ube3a. As expected, treatment of AS::Top1wt/fl neurons with topotecan led
to unsilencing of paternal Ube3a in WT and Top1 heterozygous mutant neurons (Fig 4B).
However, complete deletion of Top1 did not significantly increase UBE3A levels in AS::Top1fl/fl
neurons (Fig 4C). Moreover, compared to WT neurons, Top1 cKO neurons exhibited blunted
Ube3a unsilencing after treatment with topotecan (Fig 4C).
To replicate our findings using a different genetic approach, we utilized the CRISPR-Cas9
system to delete Top1 in wildtype (WT) and AS cortical neuron cultures. WT cells were trans-
fected with Cas9 alone (control) or Cas9 with an sgRNA directed to Top1. We observed a near-
complete loss of TOP1 using a sgRNA targeted to Top1 relative to controls (Fig 5A and 5B,
S4A Fig). Consistent with our Top1 cKO studies above, Top1 CRISPR-mediated deletion did
not increase UBE3A expression (Fig 5A and 5B). In contrast, UBE3A levels were increased in
topotecan-treated neurons (Fig 5A and 5B), but not in topotecan-treated Top1 deficient
Fig 3. TOP1 deletion reduces synaptic adhesion protein levels. (A) Top1fl/fl neuron cultures were infected with tdTomato (WT) or tdTomato-P2A-CRE
(Top1 cKO) lentivirus at DIV 3. Cells were then treated at DIV 15 with vehicle (DMSO) or 300 nM topotecan for 72 hours. Shown are representative
immunoblots with antibodies to NRXN1, NLGN1, CNTNAP2, TOP1, and ACTIN. (B) Quantification of fold change in TOP1, NRXN1, NLGN1, and
CNTNAP2 protein expression normalized to ACTIN. Mean ± s.e.m., unpaired student’s t-test; * p < 0.05, n = 3 cultures.
doi:10.1371/journal.pone.0156439.g003
TOP1 Regulation of Gene Expression in Neurons
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neurons. To examine changes in paternal UBE3A expression, we transfected Cas9 and the
sgRNA targeting Top1 into AS neurons. Consistent with our Top1 cKO studies above,
CRISPR-mediated deletion of Top1 was not sufficient to increase UBE3A in AS cortical neu-
rons (Fig 5C and 5D). Moreover, the increase in paternal UBE3A expression in topotecan-
treated AS neurons was attenuated in topotecan-treated Top1 deficient neurons (Fig 5C and
5D).
Formation of TOP1 Cleavage Complexes Unsilences Ube3a
Since deletion of Top1 did not unsilence Ube3a, whereas topotecan (which forms TOP1cc’s)
did unsilence Ube3a, we hypothesized that TOP1cc’s may be required to unsilence Ube3a in
neurons. To test this hypothesis, we compared topotecan to a series of TOP1 catalytic inhibi-
tors that inhibit TOP1 without forming TOP1cc’s (S5A Fig) [28,29]. As previously found [13],
topotecan unsilenced the paternal Ube3a-YFP allele in Ube3am+/pYFP cortical cultures
Fig 4. Top1 deletion does not efficiently unsilence the paternalUbe3a allele. (A) Schematic of the experimental setup used to assessUbe3a
unsilencing. (B,C) Representative immunoblots and quantification of indicated protein levels normalized to ACTIN in neurons from Ube3am-/p+::Top1wt/fl
mice (B) or Ube3am-/p+::Top1fl/flmice (C). Mean ± s.e.m., unpaired student’s t-test; * p < 0.05, n = 3–4 cultures.
doi:10.1371/journal.pone.0156439.g004
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Fig 5. TOP1 is necessary but not sufficient to unsilenceUbe3a. (A) WT cortical neuron cultures were transfected with
tdTomato and Cas9 alone (Ctrl.) or Cas9 and a sgRNA directed to Top1 at DIV 3. Neurons were then treated with vehicle (DMSO)
or 300 nM topotecan for 72 hours. Scale bar, 20 μm. (B) Quantification of TOP1 (top) or UBE3A (bottom) fluorescence. Values
were normalized to the fluorescence intensity of control neurons. Mean ± s.e.m., unpaired student’s t-test; * p < 0.05, n = 3
cultures. (C) Ube3am-/p+ (AS) cortical neuron cultures were transfected with tdTomato and Cas9 alone (Ctrl.) or Cas9 and a
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(S5B and S5C Fig). However, paternal Ube3a-YFP was not unsilenced after treating with four
different TOP1 catalytic inhibitors, including CYB-L10 [29], over a range of doses (S5B and
S5C Fig). CYB-L10 did significantly reduce expression of synaptic adhesion molecules in wild-
type cells (S5D and S5E Fig), suggesting the drug can enter cells and reduce expression of genes
that are affected by Top1 deletion.
We further tested the importance of TOP1cc’s in the mechanism of Ube3a unsilencing by
evaluating how a TOP1 cleavage complex mimetic (T718A) affected Ube3a expression. This
TOP1 T718A point mutation slows the DNA religation rate of TOP1 and was previously used
to address the functional relevance of TOP1cc’s [32,33]. In yeast, this point mutation is lethal
[32], but we found that postmitotic cortical neurons tolerated expression for at least 7 days
(S6A Fig). In cultured neurons, the TOP1 T718A mutant increased TOP1-DNA covalent com-
plexes compared to GFP or WT TOP1 (S6A and S6B Fig). We co-transfected AS::Top1fl/fl corti-
cal neurons with CRE to selectively delete Top1 and with plasmids expressing GFP,
GFP-TOP1, or GFP-TOP1 T718A (Fig 6A) and then monitored changes in UBE3A protein
levels. We found that overexpression of the T718A point mutation upregulated paternal
UBE3A, whereas GFP and GFP-TOP1 alone had no effect (Fig 6A and 6B). Taken together,
these data suggest that TOP1cc formation can unsilence the paternal copy of Ube3a.
Discussion
Topoisomerases have been extensively studied in the cancer field [2,4], but their contribution
to nervous system function is only beginning to emerge. Here, we created a Top1 cKO mouse
to elucidate the mechanisms governing TOP1-dependent gene regulation in postmitotic neu-
rons. Surprisingly, we found that deletion of Top1 results in down- and upregulation of only a
fraction of genes compared to treatment with the TOP1 inhibitor, topotecan (Fig 2C and 2D).
Topotecan does not further reduce transcript levels in Top1 cKO neurons, suggesting that the
transcriptional effects of topotecan are dependent on TOP1. We also found that genetic dele-
tion of Top1 reduced the expression of a subset of long genes, as has been demonstrated previ-
ously [22]; however the consequences of genetic deletion were smaller than the effects of
topotecan treatment (Fig 2B). Like topotecan, Top1 deletion decreased protein levels of synap-
tic adhesion molecules such as NEUREXIN-1, NEUROLIGIN-1, and CNTNAP2 [23], all of
which are encoded by extremely long genes. However, unlike in topotecan-treated neurons, we
found that Top1 deletion was not sufficient to unsilence Ube3a, nor was it sufficient to decrease
the expression of IEGs. Using TOP1 catalytic inhibitors that block TOP1 unwinding activity
but do not create TOP1cc’s [28,29], we observed decreased expression of synaptic adhesion
proteins but no Ube3a unsilencing, even at the highest doses tested. However, expression of a
TOP1 cleavage complex mimetic (T718A) was sufficient to unsilence Ube3a. Taken together,
our findings strongly indicate that TOP1cc’s contribute to repression of the Ube3a-ATS, and
unsilencing of the paternal Ube3a allele in neurons, and may be critical for repression of a mul-
titude of neuronal genes (Fig 6C).
Here we identified two mechanisms underlying TOP1-dependent dysregulation of gene
expression in neurons (Fig 6C). 1) Expression of TOP1cc-dependent genes are affected follow-
ing topotecan treatment but not changed following Top1 knockout (Fig 6C, left). Most of these
differentially expressed genes (n = ~500) require the formation of TOP1cc’s and are long
sgRNA directed to Top1 at DIV 3. Neurons were then treated with vehicle (DMSO) or 300 nM topotecan for 72 hours. Scale bar,
20 μm. (D) Quantification of TOP1 (top) or UBE3A (bottom) fluorescence. Values represent raw integrated density values divided
by a value of 1000. Mean ± s.e.m., unpaired student’s t-test relative to vehicle-treated Ctrl.; * p < 0.05, n = 3 cultures.N.D. = Not
detected.
doi:10.1371/journal.pone.0156439.g005
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(318 kb on average). An analog of topotecan (camptothecin) likewise forms TOP1cc’s and
reduces expression of numerous long genes in mammalian cell lines [24]. 2) Expression of
TOP1cc-independent genes are affected in Top1 cKO neurons but are not affected in WT neu-
rons treated with topotecan (Fig 6C, right). These genes tend to be much smaller in size (~43
kb). Additionally, a third group of genes are sensitive to both of these mechanisms: TOP1 levels
or TOP1cc’s. These genes are altered in Top1 cKO neurons and in topotecan-treated WT neu-
rons, and tend to be exceptionally long (~440 kb, 80 in total) (S4 Table). This gene list contains
synaptic adhesion molecules such as Nlgn1, Nrxn1, and Cntnap2.
Fig 6. Ube3a unsilencing is TOP1cc-dependent. (A) Ube3am-/p+::Top1fl/fl (AS) cortical neuron cultures were transfected with tdTomato-P2A-CRE and
GFP, GFP-TOP1, or the TOP1 cleavage complex mimetic GFP-TOP1 T718A at DIV 6. Cells were then fixed at DIV 13. (B) Quantification of UBE3A
immunostaining. Values are normalized to UBE3A intensity in the GFP control. Mean ± s.e.m., unpaired student’s t-test; * p < 0.05, n = 5 culture sets. (C)
Model depicting TOP1 regulation of gene transcription in neurons. Most genes (n = 500) that are downregulated following TOP1 disruption are TOP1cc-
dependent and long (on average ~318 kb), while a minority of genes (n = 33) are TOP1cc-independent and short (on average ~43 kb). Expression of
some genes (n = 80), are sensitive to TOP1cc-dependent or -independent mechanisms and are exceptionally long (on average ~444 kb). Listed are
potential factors that may coordinate with TOP1 to allow for these distinct mechanisms of TOP1-dependent gene regulation.
doi:10.1371/journal.pone.0156439.g006
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Using three different genetic approaches (conditional knockout, CRISPR-Cas9 deletion,
shRNA knockdown), we found that Top1 deletion does not significantly increase Ube3a
expression (Figs 2F, 4C and 5, S3 Fig). In contrast, overexpression of TOP1 T718A, a mutant
that stabilizes TOP1cc’s in neurons, did unsilence paternal Ube3a (Fig 6A and 6B). And, topo-
tecan, an inhibitor that forms TOP1cc’s, unsilenced paternal Ube3a. Inhibitors that do not
form TOP1cc’s, including CYB-L10, did not unsilence paternal Ube3a. These data strongly
suggest TOP1cc formation, and not loss of TOP1, drives paternal Ube3a unsilencing. However,
other mechanisms besides TOP1cc formation may promote reactivation of paternal Ube3a.
For example, TOP2 inhibitors unsilence paternal UBE3A [13], although whether these inhibi-
tors stabilize TOP1cc’s in neurons is unknown.
Additional mechanisms are known to participate in TOP1-dependent gene regulation. For
example, TOP1 promotes efficient transcription by resolving DNA supercoiling, which mini-
mizes R-loop (DNA:RNA hybrids) formation [4]. Deletion of Top1 leads to R-loop formation
and impairment of gene transcription [34]. TOP1 inhibitors that form cleavable complexes
increase R-loops in neurons [35,36], and R-loop formation is implicated in unsilencing the
paternal Ube3a allele [35]. One could envisage a model where excessive R-loops created by
stalled TOP1cc’s shut down transcription in neurons. Whether more R-loops are formed fol-
lowing TOP1cc formation relative to Top1 deletion is unknown. Although, given that Top1
deletion did not unsilence Ube3a, our data suggest that any R-loops that are formed following
Top1 deletion may not be sufficient to fully block long gene transcription and Ube3a-ATS.
TOP1cc’s may also be required to facilitate this downregulation.
Topoisomerase cleavage complexes can be converted into DNA double strand breaks and in
some cases, serve as a mechanism to initiate transcription [37,38]. In neurons, inhibition of
Top2β with etoposide increases the expression of IEGs by generating DNA double strand
breaks and recruiting transcriptional coactivators [39]. In our present study, and in previous
work [40], we found that topotecan decreased IEG expression in neuronal cultures. This is the
opposite of what was observed following Top2β inhibition. Moreover, we found that deletion
of Top1 is not sufficient to decrease IEG expression, suggesting that the formation of TOP1cc’s
downregulate IEG expression. Alternatively, decreased IEG expression might reflect an indirect
consequence of reduced spontaneous neuronal activity, which occurs following topotecan
treatment [23].
Intriguingly, the transcriptome of neurons is biased for longer genes relative to non-neuro-
nal cell types [41–43], and this length bias is more pronounced in some brain regions like pre-
frontal cortex and amygdala over other regions [41]. Moreover, these long genes are involved
in neurotransmission and synaptic function—processes that are uniquely important to neu-
rons. Our findings raise the possibility that neurons might be particularly vulnerable to tran-
scriptional deficits that originate from TOP1cc’s or TOP1 deletion.
Stalled TOP1cc’s can recruit factors that physically remove TOP1 from DNA [37,44–46].
These factors include ATM, a master DNA repair protein, and DNA-PK, which both regulate
ubiquitin-dependent turnover of TOP1 [45,47]. In the absence of these two factors, TOP1cc’s
accumulate in neurons. Misregulation of TOP1 has been observed in neurodegenerative disor-
ders [45,48,49] and missense mutations and disruptions of genes that regulate TOP1 have been
identified in individuals with autism spectrum disorders [22,50–52]. Thus, changes in
TOP1cc’s and TOP1 levels could contribute to a multitude of neurological disorders.
Supporting Information
S1 Fig. Validation of Top1 cKO. Cortical neurons were infected with tdTomato or tdTomato-
P2A-CRE lentivirus at DIV 3 and then were harvested at DIV 7 and DIV 10. Representative
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immunoblots for rabbit anti-TOP1 and mouse anti-TOP1. ACTIN was used as a loading con-
trol. Molecular weight markers are shown on the right.
(TIF)
S2 Fig. Topotecan reduces expression of immediate early genes (IEGs) in a Top1-dependent
manner but deletion of Top1 alone is not sufficient to reduce expression of IEGs. (A—H)
Quantification of transcript level changes from RNA-seq. Normalized RPKM values relative to
WT-Veh. Mean ± s.e.m. FDR< 0.1, n = 3 cultures.
(TIF)
S3 Fig. TOP1 depletion by shRNA reduces synaptic adhesion protein expression but does
not unsilence Ube3a. (A) Cortical neuron cultures were infected with scrambled (Scr) control
or Top1-shRNA lentiviruses at DIV 3. Neurons were harvested at DIV 10. Representative
immunoblots for NRXN1, NLGN1, UBE3A, TOP1, and ACTIN. (B) Quantification of fold
change in protein expression normalized to ACTIN. Mean ± s.e.m., unpaired student’s t-test;
 p< 0.05, n = 4 cultures. (C) Ube3am-/p+ (AS) cortical neuron cultures were infected with
either Scr control or Top1-shRNA at DIV 3. Neurons were harvested at DIV 10. Representative
immunoblots for UBE3A, TOP1, and ACTIN. (D) Quantification of fold change in protein
expression normalized to ACTIN. Mean ± s.e.m., unpaired student’s t-test;  p< 0.05, n = 3
cultures.
(TIF)
S4 Fig. Top1 deletion is not sufficient to unsilence Ube3a. (A) Zoomed in images of WT
(top) and AS (bottom) cortical neuron cultures were transfected with tdTomato and Cas9
alone (Ctrl.) or Cas9 and a sgRNA directed to Top1. Scale bar, 10 μm.
(TIF)
S5 Fig. TOP1 catalytic inhibitors do not unsilence Ube3a but do reduce expression of syn-
aptic adhesion proteins. (A) Structures of TOP1 catalytic inhibitors used to test Ube3a unsi-
lencing. (B) Ube3awt/YFP cortical neuron cultures were treated with Vehicle (Veh), the catalytic
TOP1 inhibitor CYB-L10, or topotecan at DIV 7 for 72 hours. Scale bar, 100 μm. (C) Dose
response curve for UBE3A-YFP paternal unsilencing following treatment with topotecan,
CY08C, CY13B, CYB-L01, or CYB-L10. (D) Cortical neuron cultures were treated with Vehicle
(Veh), the catalytic TOP1 inhibitor CYB-L10, or topotecan at DIV 7 for 72 hours. Representa-
tive immunoblots for NRXN1, NLGN1, CNTNAP2, UBE3A, and ACTIN. (E) Quantification
of fold change in protein expression normalized to ACTIN. Mean ± s.e.m., unpaired student’s
t-test;  p< 0.05, n = 3.
(TIF)
S6 Fig. TOP1 T718A point mutation increases TOP1cc’s in primary cortical neurons. (A)
WT cortical neuron cultures were transfected with tdTomato and GFP, GFP-TOP1, or the
TOP1 cleavage complex mimetic GFP-TOP1 T718A at DIV 6. Cells were then fixed at DIV 13.
TOP1cc intensity is shown using the Fire Lookup Table in FIJI. Scale bar, 50 μm. Zoomed inset
scale bar, 10 μm. (B) Quantification of TOP1cc immunostaining. Mean ± s.e.m., unpaired stu-
dent’s t-test;  p< 0.05, n = 9 cells per condition.
(TIF)
S1 Table. Fold change in transcript levels in WT-Topot, Top1 cKO-Veh, and Top1 cKO-To-
pot relative to WT-Veh cortical neuron cultures. Shown is a list of significant downregulated
and upregulated genes in each condition along with raw RPKM values from each condition.
(XLSX)
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S2 Table. Functional annotation of significant downregulated genes in each condition
using DAVID analysis.
(XLSX)
S3 Table. Functional annotation of significant upregulated genes in each condition using
DAVID analysis.
(XLSX)
S4 Table. List of Top1cc-dependent, Top1cc-independent, and Top1cc-dependent or -inde-
pendent TOP1 downregulated genes and their functional annotations. Graph of average
gene length of downregulated genes in the three classes listed above.
(XLSX)
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